Agios Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:AGIO)

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) was the recipient of some unusual options trading activity on Tuesday. Investors purchased 4,672 call options on the company. This is an increase of 1,311% compared to the average volume of 331 call options.

Analyst Ratings Changes

AGIO has been the topic of a number of recent analyst reports. Weiss Ratings restated a “sell (d)” rating on shares of Agios Pharmaceuticals in a report on Wednesday, June 24th. JPMorgan Chase & Co. cut their price target on shares of Agios Pharmaceuticals from $36.00 to $31.00 and set a “neutral” rating on the stock in a research report on Thursday, June 11th. The Goldman Sachs Group boosted their price objective on shares of Agios Pharmaceuticals from $28.00 to $32.00 and gave the company a “neutral” rating in a report on Wednesday, April 1st. HC Wainwright cut their target price on shares of Agios Pharmaceuticals from $65.00 to $50.00 and set a “buy” rating on the stock in a report on Monday, April 20th. Finally, Wall Street Zen raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, March 22nd. Six analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Agios Pharmaceuticals has a consensus rating of “Hold” and an average target price of $42.56.

Institutional Investors Weigh In On Agios Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. T. Rowe Price Investment Management Inc. acquired a new stake in shares of Agios Pharmaceuticals in the 4th quarter valued at about $25,000. Assetmark Inc. boosted its position in shares of Agios Pharmaceuticals by 37.9% during the fourth quarter. Assetmark Inc. now owns 1,317 shares of the biopharmaceutical company’s stock worth $36,000 after buying an additional 362 shares during the period. NewEdge Advisors LLC bought a new position in shares of Agios Pharmaceuticals during the first quarter worth about $40,000. Caitong International Asset Management Co. Ltd acquired a new stake in Agios Pharmaceuticals in the 4th quarter valued at approximately $49,000. Finally, Eurizon Capital SGR S.p.A. acquired a new stake in Agios Pharmaceuticals in the 4th quarter valued at approximately $72,000.

Agios Pharmaceuticals Stock Up 13.5%

Shares of AGIO traded up $5.05 on Tuesday, hitting $42.44. The company’s stock had a trading volume of 1,308,738 shares, compared to its average volume of 1,028,898. The firm’s fifty day moving average price is $30.43 and its 200-day moving average price is $29.41. Agios Pharmaceuticals has a fifty-two week low of $22.24 and a fifty-two week high of $46.00. The firm has a market capitalization of $2.52 billion, a price-to-earnings ratio of -5.87 and a beta of 0.54.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Wednesday, April 29th. The biopharmaceutical company reported ($1.69) EPS for the quarter, topping the consensus estimate of ($1.81) by $0.12. Agios Pharmaceuticals had a negative net margin of 639.84% and a negative return on equity of 34.11%. The firm had revenue of $20.75 million for the quarter, compared to the consensus estimate of $13.30 million. Agios Pharmaceuticals’s revenue for the quarter was up 137.7% compared to the same quarter last year. As a group, equities analysts predict that Agios Pharmaceuticals will post -6.28 earnings per share for the current fiscal year.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.